Bristol Myers Squibb receives positive CHMP opinion for CAR T cell therapy Breyanzi (lisocabtagene maraleucel) for relapsed or refractory DLBCL, PMBCL and FL3B

BMS

28 January 2022 - Recommendation for approval based on results from TRANSCEND NHL 001, the largest pivotal trial of patients with large B-cell lymphoma after at least two prior therapies, and TRANSCEND WORLD.

Bristol Myers Squibb today announced the CHMP of the EMA has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19 directed chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma , primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B after two or more lines of systemic therapy.

Read BMS press release

Michael Wonder

Posted by:

Michael Wonder